PGI’s innovative AI software solution provides secondary analysis of endoscopy videos to maximize the value of UC clinical trial insights

London, Ontario, Canada, August 5, 2025 – Alimentiv, a global full-service GI clinical research organization providing clinical trials, medical imaging, and precision medicine services to pharmaceutical and biotechnology industries, and PathwaysGI (PGI), a medical software company specializing in AI-driven endoscopy video assessment, have announced a strategic partnership. This collaboration will provide Alimentiv’s sponsors with seamless access to PGI’s Cumulative Disease Score (CDS) analytics for ulcerative colitis to supplement data analysis from Alimentiv’s human central readers.

PGI’s innovative AI/ML technology has been developed by leading gastroenterologists and AI experts to provide granular quantitation of disease severity and distribution that can be applied to identify changes in longitudinal comparisons that may not otherwise be detectable, particularly in small sample sizes.   The solution was developed and validated using real-world endoscopy video data from global, randomized clinical trials and is supported by peer-reviewed publications. The addition of the CDS to Alimentiv’s clinical portfolio aims to significantly enhance precision in ulcerative colitis clinical trials by providing complementary insights into traditional Mayo endoscopic scoring and video data analysis methods. 

“PGI’s core mission is to combine leading-edge technology with deep clinical experience to accelerate the development and targeting of therapies for IBD patients. We are excited to team up with Alimentiv in pursuit of this mission to make this innovative technology more readily available to Alimentiv’s sponsors,” said Kevin Wittrup, CEO and Founder at PathwaysGI.

“This marks a pivotal moment in our commitment to advancing GI clinical research,” stated Pierre Gaudreault, CEO at Alimentiv. “The addition of PGI’s AI solution to our suite of imaging solutions, will provide sponsors with deeper, more granular insights into disease progression and treatment efficacy. This will undoubtedly drive greater efficiency in trials and lead to better therapies for individuals living with ulcerative colitis.”


About Alimentiv
Alimentiv is a leading specialty GI-focused CRO, advancing frontiers of gastrointestinal (GI) clinical trials and medical research since 1986. As a global CRO offering clinical, medical imaging and precision medicine services and solutions, Alimentiv partners with pharmaceutical and biotechnology industries to advance the development of novel therapies and accelerate their time to market. Alimentiv is headquartered in London, Ontario, Canada, with a global footprint across its operations in Canada, the United States, Europe, Asia-Pacific, and Latin America. Learn more: alimentiv.com

About PathwaysGI (PGI)
PathwaysGI (PGI) is a leading innovator in the application of AI/ML machine vision technology to endoscopic video analysis and inflammatory bowel disease assessment. Headquartered in Ann Arbor, MI, PGI was founded in 2023 to commercialize foundational research conducted at Michigan Medicine under the guidance of Dr. Ryan Stidham, a recognized expert in the application of AI/ML methods for IBD disease assessment. Learn more: https://pgi.wagdesign.com/

Company Contacts
Clare McNally 
Chief Commercial Officer
clare.mcnally@alimentiv.com

Kevin Wittrup
CEO and Founder
kevin@pathwaysgi.com

Media Contacts
Alimentiv: info@alimentiv.com